Novo Nordisk has launched its Diabetes Patient Assistance Program in response to the COVID-19 pandemic for patients with diabetes who have lost health insurance coverage due to a change in job status.
The submission is supported by three phase 3 trials in adult and pediatric patients that showed dasiglucagon met the primary and all key secondary end points.
Patients with dyslipidemia and type 1 diabetes with high vs low adherence to lipid-lowering therapy were found to be at lower risk for nonfatal cardiovascular disease.
Lilly announced the launch of its Insulin Value Program to assist patients with or without commercial insurance with filling their monthly insulin prescriptions for $35.
Carbohydrate supplementation is superior to bolus insulin reductions for the prevention of hypoglycemia during exercise in people with type 1 diabetes.
In the COVID-19 pandemic, there are specific considerations that should be made for patients with diabetes, who are at greater risk for severe infection.
Applying functional data analysis to continuous glucose monitoring data can assist in identifying differences in maternal glucose control during pregnancy, which might go unnoticed using standard metrics.
